This study used pocket similarity approach to repurpose approved drugs for COVID19 and it resulted in a group of drugs that some of them are in the clinical trials ( Sildenafil, Lopinavir, Ritonavir). Other have been reported to have antiviral activity against SARS-CoV 2 in vitro ( Nelfinavir, Indinavir, Amprenavir), and the novel discovery of this study drugs that never been investigated for SARS-CoV 2 but antiviral activity have been reported before on other viruses ( depiqulinum , Gemcitabine, Raltitrexed, Aprepitant, montelukast, Ouabain, Raloxifene ), and finally, drugs that have never been associated with direct antiviral activity. ( Chlortetracycline, vardenafil, Suvorexant, Roflumilast, Citicoline, Sorafenib, Lumiracoxib, Lasofoxifene) This study provides a valuable candidate for drug design, with further docking and molecular dynamic to rank them and come up with the most promising results for clinical trials. Finally, I recommend the tetra family and Nelfinvir/Ritonavir for clinical trials.